Dupixent EOE denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Dupixent in EoE

This denial type is often the result of an administrative or coding error rather than a considered clinical judgment. Dupixent (dupilumab) received FDA approval for eosinophilic esophagitis, making a blanket "not FDA-approved" denial factually incorrect when the claim is submitted with the correct diagnosis codes and indication. The most common triggers for this denial are: the claim was coded for a different indication, the formulary system did not yet reflect the approval at the time of processing, or the prior authorization form did not specify the EoE indication explicitly.

## Why This Denial Is Immediately Contestable

Because the denial rests on a factual premise that can be directly rebutted with the FDA approval letter and product labeling, this is one of the strongest denial types to appeal. The appeal does not require clinical judgment from a reviewer — it requires only that the reviewer confirm the FDA record, which is publicly verifiable.

## Federal Appeal Framework

• Expedited peer-to-peer: Before filing a formal appeal, ask the prescriber to request a peer-to-peer review with UHC's medical director. Present the FDA approval documentation and the correct diagnosis/procedure codes. Many of these denials reverse at this stage.
• Internal appeal: File within the deadline on the denial notice. Attach the FDA approval documentation for dupilumab in EoE and the relevant sections of the current FDA-approved prescribing label.
• External review (ACA §2719 / ERISA §503): If internal appeal fails, request independent external review. File within approximately four months of the final internal denial (confirm exact deadline on the denial notice). An IRO will have no basis to uphold a denial that contradicts FDA approval status.
• Expedited track: Available if delay poses serious health risk.

## Documentation to Gather

1. FDA approval documentation: Print the current FDA product label for dupilumab, which lists the EoE indication explicitly. 2. Correct coding confirmation: Obtain written confirmation from the billing provider that the claim was submitted with the correct ICD-10 diagnosis code for EoE and the correct HCPCS/NDC code for dupilumab. 3. Prior authorization form: A copy of the submitted PA form showing the EoE indication was stated. 4. Prescriber letter: A letter citing the FDA approval, the patient's confirmed EoE diagnosis, and the clinical rationale for the prescription.

## Criteria-Mapping Structure

Attach a single-page summary at the front of the appeal packet: (1) FDA approval date and indication as printed on the label, (2) the patient's confirmed EoE diagnosis with ICD-10 code, (3) the claim date and codes submitted, (4) the text of the denial stating "not FDA-approved," and (5) the direct contradiction between (1) and (4). This framing makes the error unmistakable and creates a clear record for external review if needed.